-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Solid Tumor Drug Details: HBM-1020 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-7008 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HBM-7008 in Solid Tumor Drug Details: Bi-specific monoclonal antibody is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Metastatic Colorectal Cancer Drug Details: HBM-1020 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Metastatic Renal Cell Carcinoma Drug Details: HBM-1020...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-4003 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-4003 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Porustobart in Metastatic Melanoma Drug Details: HBM-4003 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCART20x22 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCART20x22 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCART20x22 in Follicular Lymphoma Drug Details: Gene therapy is under development for...
-
Product Insights
Polycystic Ovarian Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Drugs In Development, 2023’, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) - Drugs In Development, 2023’, provides an overview of the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Adrenal Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Adrenal Gland Disorders - Drugs In Development, 2023’, provides an overview of the Adrenal Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenal Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ovarian Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Ovarian Disease - Drugs In Development, 2023’, provides an overview of the Ovarian Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ovarian Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...